The supplemental New Drug Application for the C3G and IC-MPGN indications is supported by data from the phase 3 VALIANT study.
Q4 2024 Earnings Call Transcript March 31, 2025 Omeros Corporation beats earnings expectations. Reported EPS is $-0.54, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback